258 related articles for article (PubMed ID: 32779081)
21. The Use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety.
Pergolizzi JV; Christo PJ; LeQuang JA; Magnusson P
Drug Des Devel Ther; 2020; 14():1009-1025. PubMed ID: 32210534
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Treatments for Opioid-Induced Constipation: Systematic Review and Meta-analysis.
Nee J; Zakari M; Sugarman MA; Whelan J; Hirsch W; Sultan S; Ballou S; Iturrino J; Lembo A
Clin Gastroenterol Hepatol; 2018 Oct; 16(10):1569-1584.e2. PubMed ID: 29374616
[TBL] [Abstract][Full Text] [Related]
23. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.
Jansen JP; Lorch D; Langan J; Lasko B; Hermanns K; Kleoudis CS; Snidow JW; Pierce A; Wurzelmann J; Mortensen ER
J Pain; 2011 Feb; 12(2):185-93. PubMed ID: 21292169
[TBL] [Abstract][Full Text] [Related]
24. Peripherally acting μ-opioid antagonist for the treatment of opioid-induced constipation: Systematic review and meta-analysis.
Nishie K; Yamamoto S; Yamaga T; Horigome N; Hanaoka M
J Gastroenterol Hepatol; 2019 May; 34(5):818-829. PubMed ID: 30597600
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of methylnaltrexone for the treatment of opiod-induced constipation: a meta-analysis and systematic review.
Mehta N; O'Connell K; Giambrone GP; Baqai A; Diwan S
Postgrad Med; 2016; 128(3):282-9. PubMed ID: 26839023
[TBL] [Abstract][Full Text] [Related]
26. Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus.
Becker G; Blum HE
Lancet; 2009 Apr; 373(9670):1198-206. PubMed ID: 19217656
[TBL] [Abstract][Full Text] [Related]
27. Naloxegol: A Novel Therapy in the Management of Opioid-Induced Constipation.
Jones R; Prommer E; Backstedt D
Am J Hosp Palliat Care; 2016 Nov; 33(9):875-880. PubMed ID: 26150678
[TBL] [Abstract][Full Text] [Related]
28. Use of Peripheral μ-Opioid Receptor Antagonists for Treating Opioid-Induced Constipation among US Medicare Beneficiaries from 2014 to 2018.
Premnath N; Sumarsono A; Sedhom R; Johnson DH; Subbiah IM; Dy SM; Gupta A
J Palliat Med; 2021 Aug; 24(8):1236-1239. PubMed ID: 33872062
[No Abstract] [Full Text] [Related]
29. Alvimopan.
Neary P; Delaney CP
Expert Opin Investig Drugs; 2005 Apr; 14(4):479-88. PubMed ID: 15882122
[TBL] [Abstract][Full Text] [Related]
30. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review.
Becker G; Galandi D; Blum HE
J Pain Symptom Manage; 2007 Nov; 34(5):547-65. PubMed ID: 17900855
[TBL] [Abstract][Full Text] [Related]
31. Management of opioid-induced constipation in pregnancy: a concise review with emphasis on the PAMORAs.
Li Z; Pergolizzi JV; Huttner RP; Zampogna G; Breve F; Raffa RB
J Clin Pharm Ther; 2015 Dec; 40(6):615-9. PubMed ID: 26573866
[TBL] [Abstract][Full Text] [Related]
32. [News from the cochrane library: mu opioid antagonists for opioid-induced bowel dysfunction].
Meerpohl JJ; Timmer A
Z Gastroenterol; 2008 Sep; 46(9):917-21. PubMed ID: 18810678
[TBL] [Abstract][Full Text] [Related]
33. New approaches to the treatment of opioid-induced constipation.
Holzer P
Eur Rev Med Pharmacol Sci; 2008 Aug; 12 Suppl 1(0 1):119-27. PubMed ID: 18924451
[TBL] [Abstract][Full Text] [Related]
34. Alvimopan: a peripherally acting mu-opioid receptor antagonist.
Leslie JB
Drugs Today (Barc); 2007 Sep; 43(9):611-25. PubMed ID: 17940638
[TBL] [Abstract][Full Text] [Related]
35. Investigational opioid antagonists for treating opioid-induced bowel dysfunction.
Mozaffari S; Nikfar S; Abdollahi M
Expert Opin Investig Drugs; 2018 Mar; 27(3):235-242. PubMed ID: 29266973
[TBL] [Abstract][Full Text] [Related]
36. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.
Kurz A; Sessler DI
Drugs; 2003; 63(7):649-71. PubMed ID: 12656645
[TBL] [Abstract][Full Text] [Related]
37. Peripherally-active mu-opioid receptor antagonists for constipation in critically ill patients receiving opioids: A case-series and a systematic review and meta-analysis of the literature.
Umbrello M; Venco R; Palandri C; Racagni M; Muttini S
Neurogastroenterol Motil; 2023 Dec; 35(12):e14694. PubMed ID: 37869768
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of Naldemedine on Intestinal Hypomotility and Adhesions in Rodent Models of Postoperative Ileus.
Azuma Y; Koike K; Chiba H; Mitamura A; Tsuji H; Kawasaki S; Yokota T; Kanemasa T; Morioka Y; Suzuki T; Fujita M
Biol Pharm Bull; 2023 Dec; 46(12):1714-1719. PubMed ID: 37853612
[TBL] [Abstract][Full Text] [Related]
39. Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel.
De Giorgio R; Zucco FM; Chiarioni G; Mercadante S; Corazziari ES; Caraceni A; Odetti P; Giusti R; Marinangeli F; Pinto C
Adv Ther; 2021 Jul; 38(7):3589-3621. PubMed ID: 34086265
[TBL] [Abstract][Full Text] [Related]
40. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain.
Webster L; Jansen JP; Peppin J; Lasko B; Irving G; Morlion B; Snidow J; Pierce A; Mortensen E; Kleoudis C; Carter E
Pain; 2008 Jul; 137(2):428-440. PubMed ID: 18164818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
